Fourthly, considering a higher dosage of ESA related risk of CV events [52,53] and HIF-PHIs only increase EPO in the physiological level, whether the target Hb level could be upregulated with HIF-PHIs treatment for anemia treatment is yet to be studied. This evidence concerns the gene GSTM1 and anemia (phenotype).